Key terms

About SLP

Simulations Plus, Inc. provides modeling and simulation software and consulting services supporting drug discovery, development research and regulatory submissions. The firm operates through the Software and Services segment. It designs and develops pharmaceutical simulation software to promote cost-effective solutions to a number of problems in pharmaceutical research and in the education of pharmacy and medical students. The company was founded by Walter S. Woltosz and Virginia E. Woltosz on July 17, 1996 and is headquartered in Lancaster, CA.

Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest SLP news

Apr 04 8:38am ET Simulations Plus announces U.S. FDA renewed license to DILIsym platform Apr 03 6:56pm ET Simulations Plus backs FY24 EPS view 66c-68c, consensus 66c Apr 03 6:55pm ET Simulations Plus reports Q2 EPS 20c, consensus 19c Apr 03 4:23pm ET Simulations Plus Q2 Financial Performance and Outlook Warning Apr 03 7:05am ET Options Volatility and Implied Earnings Moves Today, April 03, 2024 Apr 01 8:36am ET Craig-Hallum Remains a Buy on Simulations Plus (SLP) Apr 01 7:00am ET Options Volatility and Implied Earnings Moves This Week, April 01 – April 05, 2024 Mar 28 9:20am ET Analysts Offer Insights on Healthcare Companies: PAVmed (PAVM) and Simulations Plus (SLP) Mar 05 9:11am ET FDA awards Simulations Plus a grant through proposal with University of Bath Feb 28 5:55am ET Simulations Plus management to meet with Oppenheimer Feb 27 4:55am ET Simulations Plus management to meet with Oppenheimer Feb 20 8:37am ET Simulations Plus management to meet with Oppenheimer Feb 15 9:05am ET Simulations Plus extends pact with Translational Toxicology Division at NIEHS Feb 13 9:32am ET Simulations Plus to Present at Oppenheimer Conference Feb 12 4:13pm ET Simulations Plus Shareholders Elect Board, Boost Growth Plan Jan 09 8:37am ET Simulations Plus teams with NEU and The TIM Company through new FDA grant

No recent news articles are available for SLP

No recent press releases are available for SLP

SLP Financials

1-year income & revenue

Key terms

SLP Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

SLP Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms